drugset / Trial / NCT04478461
Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase Ia, single-center, open label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and anti-tumor efficacy of MW11 (a recombinant humanized anti-PD-1 monoclonal antibody) for injection in patients with advanced solid tumors.
Timeline
- Start
- 2020-09-03
- Primary completion
- 2023-01-05
- Completion
- 2023-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MW11 | Monoclonal antibody | 1 mg/kg | — |
| Subject | MW11 | Monoclonal antibody | 3 mg/kg | — |
| Subject | MW11 | Monoclonal antibody | 10 mg/kg | — |
| Subject | MW11 | Monoclonal antibody | 200 mg | — |